A Case of Recalcitrant Psoriasis Treated with Secukinumab

Abstract

Psoriasis is a chronic, inflammatory papulosquamous disorder characterized by erythematous, scaly plaques. Treatment for recalcitrant cases can be challenging. This case report discusses the successful management of a 55 year old male with recalcitrant psoriasis, treated with Secukinumab, an IL-17A monoclonal antibody. After failing multiple therapies, including methotrexate and cyclosporine, the patient showed significant improvement following Secukinumab administration, emphasizing the effectiveness of this biologic agent in managing moderate to severe psoriasis.